- Home
- ASND vs QGEN Comparison
ASND vs QGEN Comparison
Compare ASND & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- QGEN
- Stock Information
- Founded
- ASND 2006
- QGEN 1986
- Country
- ASND Denmark
- QGEN Netherlands
- Employees
- ASND N/A
- QGEN N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASND Health Care
- QGEN Health Care
- Exchange
- ASND Nasdaq
- QGEN Nasdaq
- Market Cap
- ASND 10.6B
- QGEN 10.3B
- IPO Year
- ASND 2015
- QGEN 1996
- Fundamental
- Price
- ASND $205.91
- QGEN $47.56
- Analyst Decision
- ASND Strong Buy
- QGEN Buy
- Analyst Count
- ASND 16
- QGEN 8
- Target Price
- ASND $240.75
- QGEN $51.01
- AVG Volume (30 Days)
- ASND 510.4K
- QGEN 1.4M
- Earning Date
- ASND 08-07-2025
- QGEN 11-05-2025
- Dividend Yield
- ASND N/A
- QGEN 3.18%
- EPS Growth
- ASND N/A
- QGEN 405.09
- EPS
- ASND N/A
- QGEN 1.69
- Revenue
- ASND $576,332,355.00
- QGEN $2,040,067,000.00
- Revenue This Year
- ASND $101.37
- QGEN $7.22
- Revenue Next Year
- ASND $76.17
- QGEN $5.66
- P/E Ratio
- ASND N/A
- QGEN $28.08
- Revenue Growth
- ASND 54.50
- QGEN 5.15
- 52 Week Low
- ASND $111.09
- QGEN $37.63
- 52 Week High
- ASND $207.00
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- ASND 68.12
- QGEN 45.68
- Support Level
- ASND $195.00
- QGEN $46.27
- Resistance Level
- ASND $203.59
- QGEN $47.38
- Average True Range (ATR)
- ASND 6.41
- QGEN 0.71
- MACD
- ASND 0.27
- QGEN -0.20
- Stochastic Oscillator
- ASND 93.94
- QGEN 42.05
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).